This study aimed to assess whether transcatheter edge-to-edge repair (TEER) positively impacts patients with cardiogenic shock and mitral regurgitation. In this touchCARDIO interview, we speak with Dr Mohamad Alkhouli (Mayo Clinic School of Medicine, Rochester, MN, USA) to discuss the TVT registry and the patient population who are the best candidates for TEER.
The abstract entitled ‘Transcatheter Edge-to-Edge Repair in Patients With Severe Mitral Regurgitation and Cardiogenic Shock: Insights From the TVT Registry’ was presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference, 16 – 19, September 2022.
Questions:
- What are the unmet needs in the treatment of cardiogenic shock with significant mitral regurgitation? (0:15)
- What is known about the impact of transcatheter edge-to-edge repair (TEER) on haemodynamics and clinical outcomes of patients with cardiogenic shock and mitral regurgitation? (1:06)
- Could you give us a brief overview of the TVT registry and its aims? (1:56)
- What have been the major insights from the registry regarding TEER in this treatment setting? (3:45)
- Which patients are the best candidates for TEER and in whom is it contraindicated? (5:46)
Disclosures: Mohamad Alkhouli has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of TCT 2022
Access more content on Devices here
